Why ethical frameworks fail to deliver in a pandemic: Are proposed alternatives an improvement?


Journal

Bioethics
ISSN: 1467-8519
Titre abrégé: Bioethics
Pays: England
ID NLM: 8704792

Informations de publication

Date de publication:
10 2023
Historique:
revised: 18 05 2023
received: 30 08 2022
accepted: 31 05 2023
medline: 25 9 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: ppublish

Résumé

In the past decade, numerous ethical frameworks have been developed to support public health decision-making in challenging areas. Before the COVID-19 pandemic began, members of the authorship team were involved in research programmes, in which the development of ethical frameworks was planned, to guide (a) the use of new technologies for emerging infectious disease surveillance; and (b) the allocation of scarce supplies of pandemic influenza vaccine. However, as the pandemic evolved, significant practical challenges emerged that led to our questioning the value of these frameworks. We now believe that a normative instrument, such as a framework, cannot adequately or reliably provide the ethical guidance that needs to be incorporated into public health decision-making during natural disasters or infectious disease emergencies. Recently it has been suggested that there are potentially more dynamic, flexible, and effective ways to navigate decisions involving complex considerations entailed in policies and practices during a public health emergency. In this paper, we first outline the key functions of a public health ethics framework, before describing why we believe it would not be fit for purpose during a crisis. We end by considering whether proposed alternative methods to promote ethical public health decision-making goals have the potential to meet these objectives.

Identifiants

pubmed: 37448131
doi: 10.1111/bioe.13202
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

806-813

Informations de copyright

© 2023 The Authors. Bioethics published by John Wiley & Sons Ltd.

Références

Bioethics. 2023 Oct;37(8):806-813
pubmed: 37448131

Auteurs

Chris Degeling (C)

Australian Centre for Health Engagement, Evidence and Values, Faculty for the Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, New South Wales, Australia.

Jane Williams (J)

Australian Centre for Health Engagement, Evidence and Values, Faculty for the Arts, Social Sciences and Humanities, University of Wollongong, Wollongong, New South Wales, Australia.

Gwendolyn L Gilbert (GL)

Sydney Institute for Infectious Diseases, University of Sydney, Sydney, New South Wales, Australia.

Jane Johnson (J)

Department of Philosophy, Macquarie University, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH